3138 results for «2775»

Filter By

3138 results

Is only fixing functional mitral regurgitation in heart failure patients enough?

20 Nov 2023 – From PCR London Valves 2023

This session offers insights into combo therapy involving Carillon for patients with functional mitral regurgitation. It covers details of the EMPOWER trial, a double-blinded, sham-controlled study, and explores the potential benefits of early treatment for patients with functional mitral regurgitation.

Is only fixing functional mitral regurgitation in heart failure patients enough?

Essentials of lifetime management of TAVI patients

20 Nov 2023 – From PCR London Valves 2023

In this session, discover the key features and benefits of next-generation transcatheter heart valve technology. Gain insights into managing bicuspid and valve-in-valve interventions, and understand the procedural and clinical significance of intermediate and XL sizes in addressing unmet clinical needs.

Essentials of lifetime management of TAVI patients

Expert roundtable: 4D ICE in tricuspid interventions

20 Nov 2023 – From PCR London Valves 2023

Join this session if you want to get familiar with the 4D ICE technology and the key elements of image guidance for tricuspid interventions, understand how 4D ICE can assist in specific procedural steps during challenging tricuspid interventions, and engage in an interactive discussion with experts...

Expert roundtable: 4D ICE in tricuspid interventions

Advancing valve repair: mastering diverse mitral and tricuspid regurgitation anatomies with the PASCAL Precision system

20 Nov 2023 – From PCR London Valves 2023

Participate in this session to stay informed about the latest clinical and real-world evidence for mitral and tricuspid TEER using PASCAL. Explore case-based discussions on mitral regurgitation treatment using PASCAL Precision, and actively participate in an educational tricuspid TEER recorded case procedure featuring the PASCAL Precision.

Advancing valve repair: mastering diverse mitral and tricuspid regurgitation anatomies with the PASCAL Precision system

Mitral Late-Breaking Trials: CLASP IID, AltaValve transseptal programme, MitraSwiss in men and women, MiCLASP...

19 Nov 2023 – From PCR London Valves 2023

Discover the mitral late-breaking trials which were presented during PCR London Valves 2023: 

  • One-year outcomes of transcatheter mitral repair from the CLASP IID Registry
  • AltaValve transseptal programme update
  • Mitral TEER in men and women from MitraSwiss registry: is equality achieved?
  • Combined impact of mitral valve gradients and mitral regurgitation reduction...
Mitral Late-Breaking Trials - PCR London Valves 2023

Defying complexity: achieving optimal TAVI procedural outcomes in challenging anatomies with the new Evolut FX

20 Nov 2023 – From PCR London Valves 2023

Watch this session to understand factors to consider when deciding on valve selection, recognize the significance of device choice and implantation technique in redo-TAVI, and acquire insights into anticipating challenges associated with implanting a bicuspid valve, large anatomy, and a horizontal aorta.

Defying complexity: achieving optimal TAVI procedural outcomes in challenging anatomies with the new Evolut FX

TAVI unleashed: optimisation of immediate and long-term outcomes

20 Nov 2023 – From PCR London Valves 2023

Consult this session if you want to gain insights into the effects of paravalvular leak, conduction disturbances, stroke, and permanent pacemaker issues following transcatheter aortic valve implantation. The discussion also delves into the design of transcatheter heart valves and its implications for selecting the initial valve...

TAVI unleashed: optimisation of immediate and long-term outcomes

Tricuspid Late-Breaking Trials: TRISCEND at 2 years, TEER in primary tricuspid regurgitation, TriCLASP, bRIGHT...

19 Nov 2023 – From PCR London Valves 2023

Discover the tricuspid late-breaking trials which were presented during PCR London Valves 2023: 

  • TRISCEND study two-year outcomes: transfemoral TTVR
  • Transcatheter edge-to-edge repair in patients with primary tricuspid regurgitation
  • One-year outcomes of transcatheter tricuspid valve repair from the TriCLASP study
  • TTVR with the LuX-Valve system: one-year outcomes of a multicentre experience
  • Real-world...
Tricuspid Late-Breaking Trials

Tricuspid transcatheter valve replacement: Cardiovalve keeps things in motion

20 Nov 2023 – From PCR London Valves 2023

Participate in this session to stay informed about the latest advancements in TTVR, receive updates on the Cardiovalve tricuspid program, and gain insights into how imaging demonstrates the concept underlying Cardiovalve transcatheter valve replacement technology.

Tricuspid transcatheter valve replacement: Cardiovalve keeps things in motion

Essentials of lifetime management of TAVI patients

21 Nov 2023 – From PCR London Valves 2023

Consult this session if you want to learn about the next generation transcatheter heart valve technology key features, procedural and clinical benefits, to learn tips and tricks for managing bicuspid and valve-in-valve interventions, and to understand procedural and clinical relevance of intermediate and XL sizes in...

Essentials of lifetime management of TAVI patients

The Top Late-Breaking Trials: TRISCEND II, TRILUMINATE at 3 years, EuroSMR score, CLASP IID, OPERA-TAVI...

19 Nov 2023 – From PCR London Valves 2023

Discover the top late-breaking trials which were presented during PCR London Valves 2023:

  • TRISCEND II: A randomised trial of transcatheter tricuspid valve replacement vs medical therapy
  • Percutaneous edge-to-edge repair for tricuspid regurgitation: TRILUMINATE trial three-year outcomes
  • Transcatheter mitral valve-in-valve vs. redo surgical replacement for degenerated bioprostheses
  • Artificial intelligence derived risk...
PCR London Valves 2023 Top Late-Breaking Trials

VitaFlow - The electrically enable self-expanding TAVI valve

21 Nov 2023 – From PCR London Valves 2023

This session provides insights into the unique design and advantages of VitaFlow Liberty for TAVI. It covers techniques to minimize microdislodgement during the procedure, identifies situations and patient types most suitable for VitaFlow Liberty, and reviews early clinical results associated with this technology.

VitaFlow - The electrically enable self-expanding TAVI valve

Facing the challenges of resource shortages - An outlook into the future of TAVI?

21 Nov 2023 – From PCR London Valves 2023

Join this session to discover strategies for optimizing care quality and patient safety, especially in resource-constrained environments. Gain insights into variations in TAVI patient treatment across European countries, understanding the associated consequences. Engage in discussions exploring potential solutions to ensure long-term, high-quality patient care despite challenges...

Facing the challenges of resource shortages - An outlook into the future of TAVI?

TAVI outcomes - Part 1

19 Nov 2023 – From PCR London Valves 2023

Learn more about TAVI outcomes with this session: examine the impact of high-gradient and discordant low-gradient aortic stenosis, discover the potential of patient-specific computer simulation, explore the critical factor of time to TAVI and its implications in decompensated aortic stenosis cases, dive into the POPular TAVI...

TAVI outcomes - Part 1

Valve performance and durability - Main considerations in selecting the right TAVI valve

20 Nov 2023 – From PCR London Valves 2023

In this session with LIVE case, participants discuss the critical role of valve selection in influencing patient outcomes. The focus includes understanding the latest clinical outcomes of supra-annular TAVI and SAVR, exploring their practical implications. The session also highlights the contribution of novel technology Evolut FX, in...

Valve performance and durability - Main considerations in selecting the right TAVI valve

TAVI and beyond: tackling coronary challenges

19 Nov 2023 – From PCR London Valves 2023

Consult this session to gain a comprehensive understanding of the crucial role of coronary access post-TAVI, and the impact of TAV design and implantation technique on coronary access. Gain some insights into the intricacies of coronary accessibility from extensive bench test work and the impact of TAV design in...

TAVI and beyond: tackling coronary challenges

The catheter-based treatment revolution is just getting started

19 Nov 2023 – From PCR London Valves 2023

Consult this session to stay updated on the latest advancements in transcatheter aortic valve implantations and interventions for tricuspid regurgitation. Gain insights into how recent evidence and innovations are reshaping the treatment landscape for valvular heart disease.

The catheter-based treatment revolution is just getting started

A problem and a solution: aortic regurgitation and the Trilogy TAVI valve

19 Nov 2023 – From PCR London Valves 2023

Consult this session if you want to understand the challenges of imaging for aortic regurgitation and how it can lead to underdiagnosis. Discover the data from the ALIGN-AR trial studying TAVI in aortic regurgitation patients, and learn about the Trilogy valve and the future of TAVI...

A problem and a solution: aortic regurgitation and the Trilogy TAVI valve

Advancements in intracoronary imaging and intervention: unmasking vulnerable plaques and optimising durable PCI outcomes

16 May 2024 – From EuroPCR 2024

Delve into this EuroPCR 2024 session to gain insights into NIRS IVUS, exploring its applications, supported by current data, and understanding its clinical significance. Learn how to utilize NIRS IVUS in PCI planning through case examples, addressing lesion characteristics such as length and calcific nodules. Explore local...

Advancements in intracoronary imaging and intervention: unmasking vulnerable plaques and optimising durable PCI outcomes

Targeting inflammation in AMI: a debate

14 May 2024 – From EuroPCR 2024

Watch this session to explore inflammation's role in AMI, from atherosclerosis to post-infarct remodeling. Find out more about IL-6's significance in future MACE risk and cardiac status deterioration post-AMI, and delve into targeting inflammation via IL-6, evaluating short and long-term impacts.

Targeting inflammation in AMI: a debate
Didn’t find what you were looking for?